These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 38609177

  • 1. Pathogenic variant detection rate varies considerably in male breast cancer families and sporadic cases: minimal additional contribution beyond BRCA2, BRCA1 and CHEK2.
    Evans DG, Burghel GJ, Howell SJ, Pugh S, Forde C, Howell A, Lalloo F, Woodward ER.
    J Med Genet; 2024 Aug 29; 61(9):853-855. PubMed ID: 38609177
    [Abstract] [Full Text] [Related]

  • 2. Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer.
    Fostira F, Saloustros E, Apostolou P, Vagena A, Kalfakakou D, Mauri D, Tryfonopoulos D, Georgoulias V, Yannoukakos D, Fountzilas G, Konstantopoulou I.
    Breast Cancer Res Treat; 2018 May 29; 169(1):105-113. PubMed ID: 29335925
    [Abstract] [Full Text] [Related]

  • 3. Germline testing of BRCA1, BRCA2, PALB2 and CHEK2 c.1100delC in 1514 triple negative familial and isolated breast cancers from a single centre, with extended testing of ATM, RAD51C and RAD51D in over 400.
    Woodward ER, Lalloo F, Forde C, Pugh S, Burghel GJ, Schlecht H, Harkness EF, Howell A, Howell SJ, Gandhi A, Evans DG.
    J Med Genet; 2024 Mar 21; 61(4):385-391. PubMed ID: 38123987
    [Abstract] [Full Text] [Related]

  • 4. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL.
    Breast Cancer Res; 2011 Feb 28; 13(1):R20. PubMed ID: 21356067
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2.
    Yadav S, Boddicker NJ, Na J, Polley EC, Hu C, Hart SN, Gnanaolivu RD, Larson N, Holtegaard S, Huang H, Dunn CA, Teras LR, Patel AV, Lacey JV, Neuhausen SL, Martinez E, Haiman C, Chen F, Ruddy KJ, Olson JE, John EM, Kurian AW, Sandler DP, O'Brien KM, Taylor JA, Weinberg CR, Anton-Culver H, Ziogas A, Zirpoli G, Goldgar DE, Palmer JR, Domchek SM, Weitzel JN, Nathanson KL, Kraft P, Couch FJ.
    J Clin Oncol; 2023 Mar 20; 41(9):1703-1713. PubMed ID: 36623243
    [Abstract] [Full Text] [Related]

  • 8. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.
    Pritzlaff M, Summerour P, McFarland R, Li S, Reineke P, Dolinsky JS, Goldgar DE, Shimelis H, Couch FJ, Chao EC, LaDuca H.
    Breast Cancer Res Treat; 2017 Feb 20; 161(3):575-586. PubMed ID: 28008555
    [Abstract] [Full Text] [Related]

  • 9. High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer.
    Evans DG, van Veen EM, Byers HJ, Evans SJ, Burghel GJ, Woodward ER, Harkness EF, Eccles DM, Greville-Haygate SL, Ellingford JM, Bowers NL, Pereira M, Wallace AJ, Howell SJ, Howell A, Lalloo F, Newman WG, Smith MJ.
    J Med Genet; 2022 Feb 20; 59(2):115-121. PubMed ID: 33758026
    [Abstract] [Full Text] [Related]

  • 10. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
    de Juan I, Palanca S, Domenech A, Feliubadaló L, Segura Á, Osorio A, Chirivella I, de la Hoya M, Sánchez AB, Infante M, Tena I, Díez O, Garcia-Casado Z, Vega A, Teulé À, Barroso A, Pérez P, Durán M, Carrasco E, Juan-Fita MJ, Murria R, Llop M, Barragan E, Izquierdo Á, Benítez J, Caldés T, Salas D, Bolufer P.
    Fam Cancer; 2015 Dec 20; 14(4):505-13. PubMed ID: 26026974
    [Abstract] [Full Text] [Related]

  • 11. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.
    Falchetti M, Lupi R, Rizzolo P, Ceccarelli K, Zanna I, Calò V, Tommasi S, Masala G, Paradiso A, Gulino A, Giannini G, Russo A, Palli D, Ottini L.
    Breast Cancer Res Treat; 2008 Jul 20; 110(1):161-7. PubMed ID: 17661168
    [Abstract] [Full Text] [Related]

  • 12. Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
    Boddicker NJ, Hu C, Weitzel JN, Kraft P, Nathanson KL, Goldgar DE, Na J, Huang H, Gnanaolivu RD, Larson N, Yussuf A, Yao S, Vachon CM, Trentham-Dietz A, Teras L, Taylor JA, Scott CE, Sandler DP, Pesaran T, Patel AV, Palmer JR, Ong IM, Olson JE, O'Brien K, Neuhausen S, Martinez E, Ma H, Lindstrom S, Le Marchand L, Kooperberg C, Karam R, Hunter DJ, Hodge JM, Haiman C, Gaudet MM, Gao C, LaDuca H, Lacey JV, Dolinsky JS, Chao E, Carter BD, Burnside ES, Bertrand KA, Bernstein L, Auer PW, Ambrosone C, Yadav S, Hart SN, Polley EC, Domchek SM, Couch FJ.
    J Clin Oncol; 2021 Nov 01; 39(31):3430-3440. PubMed ID: 34292776
    [Abstract] [Full Text] [Related]

  • 13. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA, Baig MK, Milewski B, Keywan C, Guarino M, Petrelli N.
    Ann Surg Oncol; 2016 May 01; 23(5):1729-35. PubMed ID: 26727920
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series.
    Sukumar J, Kassem M, Agnese D, Pilarski R, Ramaswamy B, Sweet K, Sardesai S.
    Breast Cancer Res Treat; 2021 Apr 01; 186(2):569-575. PubMed ID: 33507482
    [Abstract] [Full Text] [Related]

  • 16. Detection of pathogenic variants in breast cancer susceptibility genes in bilateral breast cancer.
    Evans DG, Burghel GJ, Schlecht H, Harkness EF, Gandhi A, Howell SJ, Howell A, Forde C, Lalloo F, Newman WG, Smith MJ, Woodward ER.
    J Med Genet; 2023 Oct 01; 60(10):974-979. PubMed ID: 37055167
    [Abstract] [Full Text] [Related]

  • 17. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
    Petridis C, Arora I, Shah V, Megalios A, Moss C, Mera A, Clifford A, Gillett C, Pinder SE, Tomlinson I, Roylance R, Simpson MA, Sawyer EJ.
    Breast Cancer Res; 2019 May 06; 21(1):58. PubMed ID: 31060593
    [Abstract] [Full Text] [Related]

  • 18. Validation of a next generation sequencing assay for BRCA1, BRCA2, CHEK2 and PALB2 genetic testing.
    Sim WC, Lee CY, Richards R, Bettens K, Mottier V, Goh LL.
    Exp Mol Pathol; 2020 Oct 06; 116():104483. PubMed ID: 32531196
    [Abstract] [Full Text] [Related]

  • 19. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
    Walsh T, Mandell JB, Norquist BM, Casadei S, Gulsuner S, Lee MK, King MC.
    JAMA Oncol; 2017 Dec 01; 3(12):1647-1653. PubMed ID: 28727877
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.